Acute Pulmonary Embolism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Acute pulmonary embolism is a common clinical challenge due to its varied clinical manifestations. It occurs when a thrombus disrupts blood flow in the pulmonary artery or its branches, typically originating from deep vein thrombosis (DVT) in the lower extremities. Consequently, risk factors for pulmonary embolism mirror those of DVT, as elucidated by Virchow's triad: hypercoagulability, venous stasis, and endothelial injury. Pulmonary embolisms result from embolized clots entering the pulmonary circulation, often appearing as multiple clots with a predilection for the lower lung lobes and bilateral involvement. While Brain Natriuretic Peptide (BNP) elevation has limited diagnostic utility in suspected PE cases, anticoagulation remains the cornerstone of treatment. Low-molecular-weight heparin (LMWH), fondaparinux, or unfractionated heparin (UFH) are viable options for anticoagulation in acute PE management. Furthermore, Vena Cava Filters serve to obstruct emboli passage, preventing their entry into the pulmonary circulation.

• In the United States, the annual incidence of pulmonary embolism ranges from 39 to 115 cases per 100,000 population, while DVT incidence ranges from 53 to 162 cases per 100,000 individuals.
  

Thelansis’s “Acute Pulmonary Embolism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Pulmonary Embolism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acute Pulmonary Embolism across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Pulmonary Embolism Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acute Pulmonary Embolism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033